Organization
The Second Hospital of Tianjin Medical University
9 abstracts
Abstract
A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.Org: Fudan University Shanghai Cancer Center, The Second Hospital of Dalian Medical University, Harbin Medical University Cancer Hospital, Liaoning Cancer Hospital & Institute, Shenyang, China, Hunan Cancer Hospital,
Abstract
Effect of combination of genomic variation–based machine learning and clinical pathology on accurate diagnosis of tumors: Lung adenocarcinoma and lung squamous cell carcinoma.Org: Nanhai People's Hospital, the Second School of Clinical Medicine, Southern Medical University, Foshan, China, The Second Hospital of Tianjin Medical University,
Abstract
Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.Org: Fudan University Shanghai Cancer Center, Jiangsu Province Hospital, The Second Hospital of Tianjin Medical University, Department of Uro-Oncology, Chongqing University Cancer Hospital, Sichuan Provincial People's Hospital, Chengdu, China,
Abstract
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with high-risk UTUC.Org: The Second Hospital of Tianjin Medical University, Tianjin, China, Tianjin Medical University Second Hospital,
Abstract
A novel approach to the treatment of high-risk non–muscle-invasive bladder cancer: Combining immune checkpoint inhibitor (ICI) and microtubule inhibitor (MTI).Org: Tianjin Medical University Second Hospital, The Second Hospital of Tianjin Medical University,
Abstract
Relationship of platelet-to-lymphocyte ratio with tumor immune microenvironment and efficacy of anti-PD-1 combined with neoadjuvant chemotherapy in muscle invasive bladder cancer.Org: The Second Hospital of Tianjin Medical University, Second Hospital of Tianjin Medical University, Tianjin, China,
Abstract
Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer.Org: The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical, Second Hospital of Tianjin Medical University,
Abstract
Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.Org: Second Hospital of Tianjin Medical University, Tianjin, China, The Second Hospital of Tianjin Medical University, The Second Hospital of Tianjin Medical University (China),
Abstract
The efficacy and safety of antibody drug conjugate for high-risk non-muscle-invasive bladder cancer.Org: Tianjin Medical University Second Hospital, The Second Hospital of Tianjin Medical University, Tianjin Hemay Pharmaceutical,